亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome

羟基氯喹 医学 安慰剂 临床终点 内科学 随机对照试验 优势比 物理疗法 安慰剂对照研究 儿科 疾病 双盲 病理 替代医学 传染病(医学专业) 2019年冠状病毒病(COVID-19)
作者
Jacques-Éric Gottenberg,Philippe Ravaud,Xavier Puéchal,Véronique Le Guern,Jean Sibilia,Vincent Goëb,Claire Larroche,Jean‐Jacques Dubost,Stéphanie Rist,Alain Saraux,Valérie Devauchelle‐Pensec,Jacques Morel,Gilles Hayem,P.Y. Hatron,Aleth Perdriger,Damien Sène,Charles Zarnitsky,Djilali Batouche,Valérie Furlan,Joëlle Bénessiano,Élodie Perrodeau,Raphaèle Séror,Xavier Mariette
出处
期刊:JAMA [American Medical Association]
卷期号:312 (3): 249-249 被引量:236
标识
DOI:10.1001/jama.2014.7682
摘要

Importance

Primary Sjögren syndrome is a systemic autoimmune disease characterized by mouth and eye dryness, pain, and fatigue. Hydroxychloroquine is the most frequently prescribed immunosuppressant for the syndrome. However, evidence regarding its efficacy is limited.

Objective

To evaluate the efficacy of hydroxychloroquine for the main symptoms of primary Sjögren syndrome: dryness, pain, and fatigue.

Design, Setting, and Participants

From April 2008 to May 2011, 120 patients with primary Sjögren syndrome according to American-European Consensus Group Criteria from 15 university hospitals in France were randomized in a double-blind, parallel-group, placebo-controlled trial. Participants were assessed at baseline, week 12, week 24 (primary outcome), and week 48. The last follow-up date for the last patient was May 15, 2012.

Interventions

Patients were randomized (1:1) to receive hydroxychloroquine (400 mg/d) or placebo until week 24. All patients were prescribed hydroxychloroquine between weeks 24 and 48.

Main Outcomes and Measures

The primary end point was the proportion of patients with a 30% or greater reduction between weeks 0 and 24 in scores on 2 of 3 numeric analog scales (from 0 [best] to 10 [worst]) evaluating dryness, pain, and fatigue.

Results

At 24 weeks, the proportion of patients meeting the primary end point was 17.9% (10/56) in the hydroxychloroquine group and 17.2% (11/64) in the placebo group (odds ratio, 1.01; 95% CI, 0.37-2.78;P = .98). Between weeks 0 and 24, the mean (SD) numeric analog scale score for dryness changed from 6.38 (2.14) to 5.85 (2.57) in the placebo group and 6.53 (1.97) to 6.22 (1.87) in the hydroxychloroquine group. The mean (SD) numeric analog scale score for pain changed from 4.92 (2.94) to 5.08 (2.48) in the placebo group and 5.09 (3.06) to 4.59 (2.90) in the hydroxychloroquine group. The mean (SD) numeric analog scale for fatigue changed from 6.26 (2.27) to 5.72 (2.38) in the placebo group and 6.00 (2.52) to 5.94 (2.40) in the hydroxychloroquine group. All but 1 patient in the hydroxychloroquine group had detectable blood levels of the drug. Hydroxychloroquine had no efficacy in patients with anti-SSA autoantibodies, high IgG levels, or systemic involvement. During the first 24 weeks, there were 2 serious adverse events in the hydroxychloroquine group and 3 in the placebo group; in the last 24 weeks, there were 3 serious adverse events in the hydroxychloroquine group and 4 in the placebo group.

Conclusions and Relevance

Among patients with primary Sjögren syndrome, the use of hydroxychloroquine compared with placebo did not improve symptoms during 24 weeks of treatment. Further studies are needed to evaluate longer-term outcomes.

Trial Registration

clinicaltrials.gov Identifier:NCT00632866
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhiweiyan完成签到,获得积分10
6秒前
24秒前
28秒前
fransiccarey完成签到,获得积分10
32秒前
小蘑菇应助Liu采纳,获得10
35秒前
36秒前
小梦完成签到,获得积分10
36秒前
Tine发布了新的文献求助10
40秒前
量子星尘发布了新的文献求助10
45秒前
完美世界应助Tine采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
Waris完成签到 ,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
左左应助科研通管家采纳,获得10
1分钟前
Akim应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
孙孙应助霖霖采纳,获得10
1分钟前
2分钟前
重要萍完成签到 ,获得积分20
2分钟前
重要萍关注了科研通微信公众号
2分钟前
2分钟前
量子星尘发布了新的文献求助10
2分钟前
2分钟前
2分钟前
lQ发布了新的文献求助10
2分钟前
2分钟前
上官若男应助lQ采纳,获得10
2分钟前
内向的火车完成签到 ,获得积分10
2分钟前
Shego完成签到,获得积分10
3分钟前
华仔应助科研通管家采纳,获得10
3分钟前
3分钟前
3分钟前
ling361完成签到,获得积分10
3分钟前
Liu发布了新的文献求助10
3分钟前
量子星尘发布了新的文献求助10
4分钟前
科研通AI5应助Master采纳,获得10
4分钟前
Liu完成签到,获得积分20
4分钟前
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976649
求助须知:如何正确求助?哪些是违规求助? 3520756
关于积分的说明 11204729
捐赠科研通 3257502
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629